Cannabis Research

Scottsdale Research Institute strives to conduct high quality, controlled scientific studies intended to ascertain the general medical safety and efficacy of cannabis and cannabis products and examine various forms of cannabis administration.

SRI is currently conducting the only federally authorized study of medical cannabis for Post-Traumatic Stress Disorder (PTSD) for military veterans in the United States

Click Here To Learn More


Dr. Suzanne A. Sisley

Dr. Sue Sisley MD is the president and principal investigator of Scottsdale Research Institute (SRI), as well as an internal medicine physician practicing in Phoenix, Arizona. Over her twenty years in practice, Dr. Sue treated many veterans who began to confide that cannabis was an effective treatment for many of their ailments, particularly PTSD. With an epidemic of veteran suicide, Dr. Sue knew she needed to look harder at what cannabis and other psychoactive plants could offer, as well as mastering how to navigate the barriers to research on criminalized drugs.


FDA Right to Try Fact Sheet

Right to Try is one pathway for patients...

View Document


Popular Media Coverage

The first ever federally-approved study to treat PTSD using marijuana

May 8, 2019

DEA Responds To Medical Marijuana Research Expansion Lawsuit

Sep 2, 2019

Last week, the federal government announced it would begin processing dozens of pending applications for the "steps necessary to improve access to marijuana research."

Connect and Follow Us

Cannabis plant

“This grant enables more rigorous study, overseen by the F.D.A., which may lead to cannabis flower becoming prescribable medicine someday. Veterans are demanding objective cannabis drug development research, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”

Cannabis plant

“Arizona Researcher Completes First Study Of Marijuana As PTSD Treatment”

Cannabis plant

“We are delighted to announce that our Phase 2 Clinical Trial of marijuana for PTSD in veterans is COMPLETE! Huge thanks to everyone who made this possible, from participants to supporters within the community. We couldn't have done this without you!”


Areas of Research

For LSD:
Scottsdale Research Institute has been licensed to make Lysergic Acid Diethylamide, or LSD for the purposed of studying its effects on terminally ill patients with end-of-life demoralization. A study conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) showed that LSD-assisted therapy helped to permanently reduce existential anxiety in those suffering from terminal illnesses.

Read this study: https://maps.org/lsd/lsd-switzerland/

For Mushrooms:
Scottsdale Research Institute has been licensed to grow psychedelic mushrooms for the purpose of studying the effects of psilocybin-assisted therapy on pain, end-of-life distress, and PTSD. Psychedelic mushrooms can be made into chocolates, tea, and other foods for easy consumption and near-precision dosing for upcoming FDA Phase 1/2 trials.

For Cannabis:
Scottsdale Research Institute has been licensed to grow its own REAL-WORLD medical-grade cannabis. This ensures the cannabis study participants receive is comparable to what they are actively using in the real world. Cannabis has been reported by countless users to reduce symptoms of pain, and PTSD, especially in veterans with chronic, treatment-resistant PTSD. Scottsdale Research Institute/F2H will begin a new FDA Phase 2 trial with Vets that report severe pain& PTSD in January 2023.

For MDMA and why SRI has been licensed to work with it:
MDMA or methylenedioxy-methamphetamine has been shown to cause psychopharmacological effects, including “Decreased feelings of fear and defensiveness, Increased feelings of well-being, Increased sociability and extroversion, Increased interpersonal trust, An alert state of consciousness,” according to Multidisciplinary Association for Psychedelic Studies (MAPS). Because of these pharmacological effects, SRI has been licensed to conduct future studies for the treatment of PTSD with MDMA-assisted therapy.